nobeastsofierce / shutterstock.com
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
The use of living cells as therapeutic agents is a revolutionary step forward, often said to be the next major development in human medicine. Cell therapies present unique therapeutic opportunities and differ significantly from conventional small molecule therapies, and also more complex biologics, in many respects: in development, production, mechanism of action, regulation, and in some cases even the ability to be copied.
While the science develops and the regulatory framework adapts to these developments, the European patent and supplementary protection certificate (SPC) framework does not change each time a new technology is established. Therefore, careful thought must be given to the strategies employed to protect cell therapies effectively, using a combination of patents, SPCs and regulatory exclusivities, to ensure that the very significant investment made in the development of these therapies is adequately compensated.
In 2009 the European Medicines Agency (EMA) approved its first cell therapy: TiGenix’s Chondrocelect, comprising autologous cartilage cells expanded ex vivo, to treat knee cartilage defects. Since then, several further cell therapies have been approved: Genzyme’s MACI and Dendreon’s Provenge, in 2013; Chiesi’s Holoclar in 2015; and GSK’s Strimvelis and MolMed’s Zalmoxis in 2016. The first stem cell therapy, Holoclar, was approved in February 2015, comprising corneal epithelial cells containing stem cells for the repair of corneal injury. The first allogeneic (donor) cell therapy, Zalmoxis, comprising genetically modified donor T cells, was approved earlier this year as an adjunct to haematopoietic stem cell (HSC) transplantation of patients with high-risk haematological malignancies.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
regulatory, patent, patenting, biosimilar, medicinal, European, patentability, SPCs